Avenciguat

艾文西呱

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameAvenciguat
Drug Alias NameArbemnifosbuvirBI-685509
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSoluble guanylate cyclase activators
TargetsSoluble guanylate cyclase
Therapy Area/IndicationsAscitesScleroderma, SystemicVaricose Veins +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[40] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesC.H. Boehringer Sohn Ag & Co. Kg
China Registration ClassN/A

Develop Information

Active CompaniesC.H. Boehringer Sohn Ag & Co. KgBoehringer Ingelheim Pharma Gmbh & Co KgBoehringer Ingelheim International Gmbh +[4] 
Inactive CompaniesN/A
Active IndicationsScleroderma, SystemicRenal Insufficiency, ChronicDiabetic Nephropathies +[4] 
Inactive IndicationsAscitesVaricose VeinsLiver Cirrhosis, Alcoholic +[7] 

Other Information

ATC CodeN/A
Related LinksN/A